Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: @milestone

This might help:

 

This  number  includes  9,495,694 shares of common stock issuable upon
          the  conversion  of  previously  issued  convertible debentures. These
          shares  have  been  previously  registered.  This number also includes
       14,618,233  shares  of  common  stock  issuable  upon  exercise  of
          outstanding  warrants previously issued to Lincoln which are currently
          exercisable,  which shares would not be deemed beneficially owned (due
          to  exercise  restrictions  within the warrants) within the meaning of
          Sections  13(d) and 13(g) of the Exchange Act to the extent that their
          acquisition  in  a  warrant exercise by Lincoln would cause Lincoln to
          own  in  excess  of  4.99% of our outstanding common stock immediately
          following  such  exercise.  By  the terms of the Debentures, the 4.99%
          limitation  may  be  increased  to  a  maximum of 9.99% if the Company
          accepts a tender offer and a change in control takes place. Therefore,
          it  is expected that Lincoln will not beneficially own more than 9.99%
          of  our  outstanding  common stock at any time. Roy Adams has ultimate
          voting and/or investment control over the securities owned by Lincoln.

http://www.secinfo.com/d12TC3.2w4.htm

 

(page 18)

 

It would appear that they kept under the 5% reporting limit until 2006.

 

 

Be well

 

 

Share
New Message
Please login to post a reply